Semaglutide and Its Rising Popularity

21 Jun 2025 GS 3 Science & Technology
    Live Views: Loading...

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist drug used for managing Type-II diabetes and obesity. It mimics a natural hormone (GLP-1) to increase insulin secretion, reduce appetite, and control blood glucose levels.

Brand Names and Use:

  • Ozempic: Approved for diabetes.

  • Wegovy: Approved for weight loss.

  • Both are injectables made by Novo Nordisk and contain semaglutide.

Popularity and Market:

  • Widely popularized as the “skinny jab” by international celebrities.

  • Semaglutide-based products earned over $29 billion globally.

  • Expected launch of Wegovy in India in June 2025.

  • The oral version is already available in India (₹10,000/month).

Competing Drugs:

  • Eli Lilly’s Mounjaro (tirzepatide): Launched in India for weight loss and diabetes; priced lower (₹3,500–₹4,375 per vial).

Patent Disputes:

  • Novo Nordisk is fighting a patent infringement case against Dr Reddy’s Laboratories (DRL) and OneSource in India.

  • A similar patent lapse in Canada (due to non-payment of maintenance fee) could open the door for generics.

Side Effects and Risks:

  • Common side effects: vomiting, diarrhoea, abdominal pain.

  • Red-flagged for possible risk of vision loss by European regulators.

  • Weight may return after stopping the drug.

  • Caution advised for individuals with thyroid disorders.

Public Health Significance:

  • Growing interest from Indian companies may make semaglutide more affordable for people with Type-II diabetes and obesity, both in India and globally.



← Back to list